{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:29:31Z","timestamp":1775683771861,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":533,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Health and Human Services"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5R01-DK067110"],"award-info":[{"award-number":["5R01-DK067110"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5R37-DK037963"],"award-info":[{"award-number":["5R37-DK037963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bbamcr.2011.11.012","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T02:55:12Z","timestamp":1323831312000},"page":"505-513","source":"Crossref","is-referenced-by-count":16,"title":["Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of Fc\u03b3RIIB receptors"],"prefix":"10.1016","volume":"1823","author":[{"given":"Li-Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali K.","family":"Yanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Z.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena M.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Liang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Fang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas C.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He-Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamcr.2011.11.012_bb0005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2741\/3719","article-title":"Understanding rituximab function and resistance: implications for tailored therapy","volume":"16","author":"Amoroso","year":"2011","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0010","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1124\/mol.104.008193","article-title":"Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases","volume":"67","author":"Beeton","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0015","doi-asserted-by":"crossref","first-page":"13942","DOI":"10.1073\/pnas.241497298","article-title":"Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis","volume":"98","author":"Beeton","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0020","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0605136103","article-title":"Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases","volume":"103","author":"Beeton","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0025","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0030","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.4049\/jimmunol.181.4.2916","article-title":"Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving","volume":"181","author":"Beum","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0045","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3109\/10428191003717746","article-title":"The future of CD20 monoclonal antibody therapy in B-cell malignancies","volume":"51","author":"Czuczman","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10495-006-6314-5","article-title":"Caspase-independent killing of Burkitt lymphoma cell lines by rituximab","volume":"11","author":"Daniels","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0055","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20062545","article-title":"Selective blockade of the inhibitory Fc\u03b3 receptor (Fc\u03b3RIIB) in human dendritic cells and monocytes induces a type I interferon response program","volume":"204","author":"Dhodapkar","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.nucmedbio.2010.05.010","article-title":"Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology","volume":"38","author":"Dias","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0065","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1189\/jlb.0608343","article-title":"A novel subset of NK cells expressing high levels of inhibitory Fc\u03b3RIIB modulating antibody-dependent function","volume":"84","author":"Dutertre","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0070","doi-asserted-by":"crossref","first-page":"15150","DOI":"10.1021\/bi0511078","article-title":"Isolation and characterization of the B-cell marker CD20","volume":"44","author":"Ernst","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0075","doi-asserted-by":"crossref","first-page":"18866","DOI":"10.1016\/S0021-9258(17)46707-X","article-title":"Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels","volume":"268","author":"Garcia-Calvo","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"Hofmeister","year":"2000","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0085","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood.V91.5.1762","article-title":"Inhibition of Fc\u03b3 receptor-mediated phagocytosis by a nonphagocytic Fc\u03b3 receptor","volume":"91","author":"Hunter","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0090","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/rheumatology\/keh488","article-title":"Intravenous immunoglobulin does not increase Fc\u03b3RIIB expression on monocytes\/macrophages during acute Kawasaki disease","volume":"44","author":"Ichiyama","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0095","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","article-title":"Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc","volume":"164","author":"Idusogie","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0100","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1074\/jbc.274.19.13704","article-title":"Fc\u03b3RIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells","volume":"274","author":"Jacob","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0105","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2010-08-301945","article-title":"CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies","volume":"117","author":"Kohrt","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.cji.0000203081.43235.d7","article-title":"Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum","volume":"29","author":"Lefebvre","year":"2006","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0115","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0120","doi-asserted-by":"crossref","first-page":"44898","DOI":"10.1074\/jbc.M106819200","article-title":"The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties","volume":"276","author":"Maenaka","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0125","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0130","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/j.1349-7006.2009.01327.x","article-title":"Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity","volume":"100","author":"Natsume","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0135","article-title":"Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes","author":"Nguyen","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0140","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.4049\/jimmunol.151.5.2462","article-title":"Pattern of potassium channel expression in proliferating B lymphocytes depends upon the mode of activation","volume":"151","author":"Partiseti","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2249.2011.04415.x","article-title":"A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide","volume":"165","author":"Piccioni","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0150","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2010-06-290858","article-title":"Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies","volume":"117","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0155","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/14728220903018957","article-title":"Kv1.3 potassium channels as a therapeutic target in multiple sclerosis","volume":"13","author":"Rangaraju","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0160","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2006-05-020602","article-title":"CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma","volume":"108","author":"Rankin","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0165","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0170","doi-asserted-by":"crossref","first-page":"30499","DOI":"10.1074\/jbc.271.48.30499","article-title":"Human type II Fcgamma receptors inhibit B cell activation by interacting with the p21(ras)-dependent pathway","volume":"271","author":"Sarmay","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0175","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/mol.105.015669","article-title":"Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases","volume":"68","author":"Schmitz","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0180","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0185","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0190","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.4049\/jimmunol.178.5.3272","article-title":"Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus","volume":"178","author":"Su","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0195","doi-asserted-by":"crossref","first-page":"20465","DOI":"10.1074\/jbc.271.34.20465","article-title":"Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation","volume":"271","author":"Szabo","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2141.2008.07555.x","article-title":"Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab","volume":"145","author":"Turzanski","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0205","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00424-007-0258-7","article-title":"An intermediate-conductance Ca2+-activated K+ channel mediates B lymphoma cell cycle progression induced by serum","volume":"454","author":"Wang","year":"2007","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0210","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1172\/JCI16921","article-title":"The voltage-gated Kv1.3 channel in effector memory T cells as new target for MS","volume":"111","author":"Wulff","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0215","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.173.2.776","article-title":"K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity","volume":"173","author":"Wulff","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00232-001-0176-0","article-title":"Incomplete inactivation of voltage-dependent K+ channels in human B lymphoma cells","volume":"188","author":"Zhou","year":"2002","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.bbamcr.2011.11.012_bb0225","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3816\/CLML.2010.n.067","article-title":"Fcgamma receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"10","author":"Zhuang","year":"2010","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488911003144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488911003144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T20:12:15Z","timestamp":1686514335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488911003144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0167488911003144"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2011.11.012","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}